China Resources Pharmaceutical Group (3320) H2 2025 earnings summary

Executive summary

• Revenue rose 4.6% year-over-year to RMB269.6 billion, with net profit up 14.9% to RMB9.65 billion and profit attributable to owners up 20.7% to RMB4.05 billion.

• Gross profit increased 9.4% to RMB44.5 billion, with gross margin improving by 0.7 percentage points to 16.5%.

• Final dividend proposed at RMB0.122 per share, up from RMB0.052 last year.

• Maintained leading industry position, with significant honors for subsidiaries and brands.

Financial highlights

• Operating cash flow reached RMB20.5 billion, up from RMB17.5 billion in 2024.

• Gearing ratio improved to 47.4% from 52.3% year-over-year.

• Current ratio stable at 1.4:1.

• Basic EPS increased to RMB0.64 from RMB0.53.

• Final dividend of RMB0.122 per share proposed, subject to approval.

Outlook and guidance

• Focus on portfolio optimization, innovation-driven growth, and external expansion through M&A and investments.

• Plans to deepen digital transformation, smart manufacturing, and international expansion.

• Commitment to operational excellence and leveraging AI across the value chain.